Abstract:Atrial fibrillation(AF) is the most common cardiac arrhythmia and an important independent stroke risk factor,especially in the elderly and female.This article provides the reader with an overview as well as an update on primary and secondary stroke prevention strategies in patients with AF.Warfarin,a vitamin K antagonist,remains the cornerstone therapy in AF patients at high risk of stroke.Meanwhile,warfarin has multiple and well-known limitations,including numerous interactions with other drugs,the need for regular blood monitoring and dose adjustments.New direct thrombin inhibitor and direct factor Xa inhibitor are at least as effective as warfarin,and lead to a significant and clinically relevant decrease in bleed profiles.However,they may not be necessary for the individual patient in whom the INR has been well controlled with warfarin for years.In addition,much novel oral anticoagulation is much more expensive than warfarin,and lack of these agents to reverse.After all this time,it is still question whether a new era of anticoagulation appears to be emerging for patients with atrial fibrillation in China.

Comparison of the new oral anticoagulant drug with warfarin to prevent stroke in patients with atrial fibrillation